DRTS
Alpha Tau Medical Ltd.
$13.09
+3.72% 2026-10-20
Healthcare
DRTSSPY
1W
-4.7%
1M
-14.1%
3M
-1.7%
6M
+65.7%
YTD
+164.4%
1Y
+227.3%
Live chart
Loading live chart…
Grades vs sector
MomentumNot enough data yet–
Momentum
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
GrowthNot enough data yet–
Growth
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Value
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
ProfitabilityNot enough data yet–
Profitability
Not enough data yet
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsAlpha Tau Medical Gets FDA Approval to Expand Brain Cancer Trial
MT Newswires · Oct 19
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
GlobeNewswire · Oct 19
Alpha Tau to Participate in October Investor Conferences
GlobeNewswire · Oct 05
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Vistra, Nike to Open Higher
MT Newswires · Oct 05
Alpha Tau to Participate in September Investor Conferences
GlobeNewswire · Sep 02
Key stats
Market cap$1.2B
P/E (trailing)–
P/E (forward)-24.5
52-week range3.43 – 15.79
Revenue growth (YoY, latest qtr)–
Dividend yield0.00%
Analyst consensusNone (5)
Mean price target$17.80 (+36%)
Valuation and fundamentals
Valuation & fundamentals
No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).
Earnings
Next report: 2026-11-19 · during market · EPS est -0.15
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-10 | -0.14 | -0.50 | -254.9% |
| 2026-05-18 | -0.12 | -0.26 | -110.4% |
| 2026-03-09 | -0.12 | -0.14 | -13.4% |
| 2025-11-20 | -0.12 | -0.14 | -21.4% |
| 2025-08-11 | -0.11 | -0.13 | -13.8% |
| 2025-05-19 | -0.13 | -0.12 | +5.8% |
| 2025-03-12 | -0.13 | -0.13 | -2.6% |
| 2024-11-19 | -0.12 | -0.10 | +16.9% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | – |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $0 | – |
| 2025-09-30 | $0 | – |
| 2025-06-30 | $0 | – |
Analyst actions
HC Wainwright & Co.
PT $16
2026-10-20 · reit
Buy → BuyPT $16
Barclays
PT $30
2026-09-03 · main
Overweight → OverweightPT $30
HC Wainwright & Co.
PT $16
2026-08-11 · main
Buy → BuyPT $16
HC Wainwright & Co.
PT $15
2026-07-22 · reit
Buy → BuyPT $15
HC Wainwright & Co.
PT $15
2026-07-16 · reit
Buy → BuyPT $15
HC Wainwright & Co.
PT $15
2026-06-04 · reit
Buy → BuyPT $15
Insider trades
Levy Raphi
$43.1K
Chief Financial Officer · 2026-08-21
SELL$43.1K
Levy Raphi
$248.3K
Chief Financial Officer · 2026-08-11
SELL$248.3K
Stats refreshed 2026-10-20 18:13:58 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.